Omkar Pharmachem returns to profitability in FY26
Omkar Pharmachem Limited returned to profitability in FY26 with a net profit of ₹12.18 lakh, compared to a loss in the prior year. Total comprehensive income for the year reached ₹2720.61 lakh, driven by other comprehensive income. The company's balance sheet strengthened significantly, with total assets rising to ₹3669.04 lakh, primarily due to an increase in other investments.
*this image is generated using AI for illustrative purposes only.
Omkar Pharmachem Limited returned to profitability in the financial year ended March 31, 2026, reporting a net profit of ₹12.18 lakh, a reversal from the previous year's performance. The company recorded a total comprehensive income of ₹2720.61 lakh for the year, significantly bolstered by other comprehensive income of ₹2708.43 lakh. The Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, during a meeting held on May 30, 2026.
For the quarter ended March 31, 2026, the company reported a profit of ₹1.50 lakh, compared to a loss of ₹2.15 lakh in the same period of the previous year. Total income for the quarter stood at ₹9.30 lakh, while total expenses were ₹7.35 lakh. The statutory auditor, M/s. Dipal R. Shah & Co., issued an unmodified opinion on the standalone financial results, confirming compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The balance sheet as of March 31, 2026, shows total assets at ₹3669.04 lakh, a substantial increase from ₹960.33 lakh in the previous year. This growth is primarily attributed to other investments, which rose to ₹3638.43 lakh from ₹930.00 lakh. Equity attributable to the owners of the company stood at ₹3663.98 lakh, compared to ₹943.37 lakh in the prior year. The company maintained a debt-free status with no borrowings recorded under non-current or current financial liabilities.
Cash flow from operating activities improved to ₹22.84 lakh in FY26 from ₹24.35 lakh in the previous year. The company generated cash primarily through operations and saw a net increase in cash and cash equivalents of ₹10.79 lakh, bringing the closing balance to ₹21.73 lakh. Investing activities remained neutral with no net cash used, while financing activities resulted in a net outflow of ₹12.06 lakh, largely due to the repayment of short-term borrowings.
Financial Performance Summary
| Metric | FY26 (₹ in lakh) | FY25 (₹ in lakh) |
|---|---|---|
| Net Sales/Income from Operations | 0.00 | 0.00 |
| Other Operating Income | 46.50 | 54.00 |
| Total Income | 47.24 | 47.24 |
| Total Expenses | 30.96 | 30.96 |
| Net Profit for the Period | 12.18 | (2.15) |
| Total Comprehensive Income | 2720.61 | 2720.61 |
Assets and Liabilities
| Particulars | As at 31-03-2026 (₹ in lakh) | As at 31-03-2025 (₹ in lakh) |
|---|---|---|
| Total Non-current Assets | 3638.90 | 933.82 |
| Total Current Assets | 30.14 | 26.51 |
| Total Assets | 3669.04 | 960.33 |
| Total Equity | 3663.98 | 943.37 |
| Total Liabilities | 5.06 | 16.96 |
Historical Stock Returns for Omkar Pharmachem
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.56% | -1.04% | -29.63% | -35.59% | -26.01% | -8.87% |
What specific investments comprise the ₹3638.43 lakh in other investments that drove the asset growth?
With zero sales from operations, what is the company's strategic plan to generate revenue in the coming fiscal year?
How does the company intend to utilize its debt-free status and increased equity to fund future business activities?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
